BEAM Valuation

Beam Therapeutics Inc

Add to Watchlist

Advanced Chart

21.720

+0.77(3.675%)1D

Overview
Forecast
Valuation
Earnings

BEAM Relative Valuation

BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BEAM is overvalued; if below, it's undervalued.

Historical Valuation

Beam Therapeutics Inc (BEAM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 34.23 is considered Undervalued compared with the five-year average of -11.26. The fair price of Beam Therapeutics Inc (BEAM) is between 160.93 to 165.61 according to relative valuation methord. Compared to the current price of 20.95 USD , Beam Therapeutics Inc is Undervalued By 86.98%.

Relative Value

Fair Zone

160.93-165.61

Current Price：20.95

86.98%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.82

P/B

Median3y

2.86

Median5y

5.60

-16.71

FCF Yield

Median3y

-9.96

Median5y

-6.75

Competitors Valuation Multiple

The average P/S ratio for BEAM's competitors is 1056.65, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of 34.23, which is -96.76% above the industry average. Given its robust revenue growth of 0.81%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BEAM.O

Beam Therapeutics Inc

34.23

Average P/S: 1056.65

0.81%